Royalderm Agnieszka Nawrocka

Warsaw, Masovian Voivodeship 02-962

1 studies enrolling now · 9 studies all time

What they study most

Active Nonsegmental Vitiligo, Alopecia Areata, Dermatitis, Atopic, Plaque Psoriasis, Severe Alopecia Areata, Stable Nonsegmental Vitiligo, Vitiligo

Studies at this site

• A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. — Recruiting now
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 — Running, not enrolling
• A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata — Running, not enrolling
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo — Running, not enrolling
• A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo — Completed
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis — Completed